- Open
- 66.00
- High
- 66.00
- Low
- 66.00
- Close
- 66.00
- Change
- -4.00 (-6.06%)
- Volume
- 6,400
⌘K
| 28 Apr 2026 | 16:28:19 | Posting of Annual Report and Notice of AGMm |
| 13 Apr 2026 | 07:00:06 | Final Results |
| 30 Mar 2026 | 07:00:12 | Notice of FY25 Results |
| 26 Mar 2026 | 07:00:10 | Ligand Pharmaceuticals Milestone Payment |
| 13 May 2025 | Annual Report and Accounts (to 2024-12-31) |
Arecor is a biopharmaceutical company with a global reach that aims to improve patient care by developing innovative medicines that enhance existing therapeutic products.
| 28 Apr 2026 | 16:28:19 | Posting of Annual Report and Notice of AGMm |
| 13 Apr 2026 | 07:00:06 | Final Results |
| 30 Mar 2026 | 07:00:12 | Notice of FY25 Results |
| 26 Mar 2026 | 07:00:10 | Ligand Pharmaceuticals Milestone Payment |
| 13 May 2025 | Annual Report and Accounts (to 2024-12-31) |
Arecor is a biopharmaceutical company with a global reach that aims to improve patient care by developing innovative medicines that enhance existing therapeutic products.
| 9 Mar 2026 |
| 07:00:14 |
| Arecor to present at Oppenheimer conference |
| 13 Apr 2026 |
| Arecor Therapeutics CEO on FY25 highlights and progress with AT278 and GLP-1 programmes |
| 26 Mar 2026 | Arecor receives $500k milestone payment from Ligand as royalty deal delivers |
| 9 Mar 2026 |
| 07:00:14 |
| Arecor to present at Oppenheimer conference |
| 13 Apr 2026 |
| Arecor Therapeutics CEO on FY25 highlights and progress with AT278 and GLP-1 programmes |
| 26 Mar 2026 | Arecor receives $500k milestone payment from Ligand as royalty deal delivers |